Advertisement

Annals of Surgical Oncology

, Volume 19, Issue 13, pp 4322–4329 | Cite as

Surgeons’ Opinions on Lymphadenectomy in Melanoma Patients with Positive Sentinel Nodes: A Worldwide Web-Based Survey

  • Sandro Pasquali
  • Andrew J. Spillane
  • Johannes H. W. de Wilt
  • Kirsten McCaffery
  • Carlo R. Rossi
  • Michael J. Quinn
  • Robyn P. Saw
  • Kerwin F. Shannon
  • Jonathan R. Stretch
  • John F. Thompson
Melanomas

Abstract

Purpose

A worldwide web-based survey was conducted among melanoma surgeons to investigate opinions about completion lymph node dissection (CLND) in patients with positive sentinel nodes (SN).

Methods

A questionnaire was designed following input from a group of melanoma surgeons. Cognitive interviews and pilot testing were performed. Surgeons identified through a systematic-review of the SN and CLND literature were invited by email.

Results

Of 337 surgeons, 193 (57.2 %) from 25 countries responded (January–July 2011). Most respondents work in melanoma (30.1 %) and surgical oncology (44.6 %) units. In patients with a positive SN, 169 (91.8 %) recommend CLND; the strength of the recommendation is mostly influenced by patient comorbidities (64.7 %) and SN tumor burden (59.2 %). Seventy-one responders enroll patients in the second Multicenter Selective-Lymphadenectomy Trial (MSLT-2), and 64 of them (76 %) suggest entering the trial to majority of patients. In cases requiring neck CLND, level 1–5 dissection is recommended by 35 % of responders, whereas 62 % base the extent of dissection on primary site and lymphatic mapping patterns. Only inguinal dissection or ilioinguinal dissection is performed by 36 and 30 % of surgeons, respectively. The remaining 34 % select either procedure according to number of positive SNs, node of Cloquet status, and lymphatic drainage patterns. Most surgeons (81 %) perform full axillary dissections in positive SN cases.

Conclusions

The majority of melanoma surgeons recommend CLND in SN-positive patients. Surgeons participating in the MSLT-2 suggest entering the trial to the majority of patients. More evidence is needed to standardize the extent of neck and groin CLND surgeries.

Keywords

Melanoma Sentinel Node Positive Sentinel Node Sentinel Node Metastasis Completion Lymph Node Dissection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

SP was a research fellow at the MIA, he was supported by the Melanoma Foundation, and the Veneto Oncology Institute, Padova, Italy. AJS’s research is supported by The Friends of the Mater Foundation, North Sydney, NSW, Australia. The authors truly thank Prof. Simone Mocellin (University of Padova, Padova, Italy) and Dr. Antonio Sommariva (Veneto Institute of Oncology, Padova, Italy) for actively participating the testing and retesting phase. The authors are thankful to all the surgeons who took part in this survey, especially to the Head of the Department as they involved their collaborators in this project. A full list of participating institutions is reported in Appendix 2.

Supplementary material

10434_2012_2483_MOESM1_ESM.pdf (315 kb)
Supplementary material 1 (PDF 315 kb)
10434_2012_2483_MOESM2_ESM.doc (20 kb)
Supplementary material 2 (DOC 19.8 kb)

References

  1. 1.
    Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer. 2010;46:270–83.PubMedCrossRefGoogle Scholar
  2. 2.
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Melanoma (version 3.2012). www.nccn.org. Accessed 6 June 2012.
  3. 3.
    Marsden JR, Newton-Bishop JA, Burrows L, et al. Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br J Dermatol. 2010;163:238–56.PubMedCrossRefGoogle Scholar
  4. 4.
    Australian Cancer Network Melanoma Guidelines Revision Working Party. Clinical practice guidelines for the management of melanoma in Australia and New Zealand. Cancer Council Australia and Australian Cancer Network, Sydney and New Zealand Guidelines Group, Wellington (2008).Google Scholar
  5. 5.
    Bilimoria KY, Balch CM, Bentrem DJ, et al. Complete lymph node dissection for sentinel node-positive melanoma: assessment of practice patterns in the United States. Ann Surg Oncol. 2008;15:1566–76.PubMedCrossRefGoogle Scholar
  6. 6.
    Livingstone E, Windemuth-Kieselbach C, Eigentler TK, et al. A first prospective population-based analysis investigating the actual practice of melanoma diagnosis, treatment and follow-up. Eur J Cancer. 2011;47:1977–89.PubMedCrossRefGoogle Scholar
  7. 7.
    Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–17.PubMedCrossRefGoogle Scholar
  8. 8.
    Pasquali S, Mocellin S, Campana LG, et al. Early (sentinel lymph node biopsy-guided) versus delayed lymphadenectomy in melanoma patients with lymph node metastases: personal experience and literature meta-analysis. Cancer. 2010;116:1201–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Ross MI, Gershenwald JE. How should we view the results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)? Ann Surg Oncol. 2008;15:670–3.PubMedCrossRefGoogle Scholar
  10. 10.
    Ross MI, Thompson JF, Gershenwald JE. Sentinel lymph node biopsy for melanoma: critical assessment at its twentieth anniversary. Surg Oncol Clin N Am. 2011;20:57–78.PubMedCrossRefGoogle Scholar
  11. 11.
    Gershenwald JE, Ross MI. Sentinel lymph node biopsy for cutaneous melanoma. N Engl J Med. 2011;364:1738–45.PubMedCrossRefGoogle Scholar
  12. 12.
    Murali R, Desilva C, Thompson JF, Scolyer RA. Non-sentinel node risk score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. J Clin Oncol. 2010;28:4441–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Murali R, Desilva C, Thompson JF, Scolyer RA. Factors predicting recurrence and survival in sentinel lymph node-positive melanoma patients. Ann Surg. 2011;253:1155–64.PubMedCrossRefGoogle Scholar
  14. 14.
    van der Ploeg AP, van Akkooi AC, Rutkowski P, et al. Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol. 2011;29:2206–14.PubMedCrossRefGoogle Scholar
  15. 15.
    van der Ploeg IM, Kroon BB, Antonini N, Valdes Olmos RA, Nieweg OE. Is completion lymph node dissection needed in case of minimal melanoma metastasis in the sentinel node? Ann Surg. 2009;249:1003–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Guggenheim MM, Hug U, Jung FJ, et al. Morbidity and recurrence after completion lymph node dissection following sentinel lymph node biopsy in cutaneous malignant melanoma. Ann Surg. 2008;247:687–93.PubMedCrossRefGoogle Scholar
  17. 17.
    Spillane AJ, Saw RP, Tucker M, Byth K, Thompson JF. Defining lower limb lymphedema after inguinal or ilio-inguinal dissection in patients with melanoma using classification and regression tree analysis. Ann Surg. 2008;248:286–93.PubMedCrossRefGoogle Scholar
  18. 18.
    Faries MB, Thompson JF, Cochran A, et al. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol. 2010;17:3324–9.PubMedCrossRefGoogle Scholar
  19. 19.
    de Vries M, Vonkeman WG, van Ginkel RJ, Hoekstra HJ. Morbidity after inguinal sentinel lymph node biopsy and completion lymph node dissection in patients with cutaneous melanoma. Eur J Surg Oncol. 2006;32:785–9.PubMedCrossRefGoogle Scholar
  20. 20.
    de Vries M, Vonkeman WG, van Ginkel RJ, Hoekstra HJ. Morbidity after axillary sentinel lymph node biopsy in patients with cutaneous melanoma. Eur J Surg Oncol. 2005;31:778–83.PubMedCrossRefGoogle Scholar
  21. 21.
    Chang SB, Askew RL, Xing Y, et al. Prospective assessment of postoperative complications and associated costs following inguinal lymph node dissection (ILND) in melanoma patients. Ann Surg Oncol. 2010;17:2764–72.PubMedCrossRefGoogle Scholar
  22. 22.
    Multicenter Selective Lymphadenectomy Trial II (MSLT-II). http://clinicaltrial.gov/ct2/show/NCT00297895?term=MSLT+2&rank=2. Accessed 29 Jan 2012.
  23. 23.
    Prospective registration study on sentinel node positive patients with minimal sentinel node tumor burden managed without complete lymph node dissection. http://www.melanomagroup.eu/site/databasefor-melanoma-group-member/minitub.html. Accessed 29 Jan 2012.
  24. 24.
    Kunte C, Geimer T, Baumert J, et al. Prognostic factors associated with sentinel lymph node positivity and effect of sentinel status on survival: an analysis of 1049 patients with cutaneous melanoma. Melanoma Res. 2010;20:330–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Bogenrieder T, van Dijk MR, Blokx WA, et al. No non-sentinel node involvement in melanoma patients with limited Breslow thickness and low sentinel node tumour load. Histopathology. 2011;59:318–26.PubMedGoogle Scholar
  26. 26.
    van der Ploeg AP, van Akkooi AC, Schmitz PI, Koljenovic S, Verhoef C, Eggermont AM. EORTC Melanoma Group sentinel node protocol identifies high rate of submicrometastases according to Rotterdam criteria. Eur J Cancer. 2010;46:2414–21.PubMedCrossRefGoogle Scholar
  27. 27.
    Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100.PubMedCrossRefGoogle Scholar
  28. 28.
    Rossi CR, Mocellin S, Pasquali S, Pilati P, Nitti D. N-ratio: a novel independent prognostic factor for patients with stage-III cutaneous melanoma. Ann Surg Oncol. 2008;15:310–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Spillane AJ, Cheung BL, Winstanley J, Thompson JF. Lymph node ratio provides prognostic information in addition to American joint committee on cancer N stage in patients with melanoma, even if quality of surgery is standardized. Ann Surg. 2011;253:109–15.PubMedCrossRefGoogle Scholar
  30. 30.
    van Akkooi AC, Voit CA, Verhoef C, Eggermont AM. New developments in sentinel node staging in melanoma: controversies and alternatives. Curr Opin Oncol. 2010;22:169–77.PubMedCrossRefGoogle Scholar
  31. 31.
    Rossi CR, De Salvo GL, Bonandini E, et al. Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node. Ann Surg Oncol. 2008;15:1202–10.PubMedCrossRefGoogle Scholar
  32. 32.
    Chu CK, Delman KA, Carlson GW, Hestley AC, Murray DR. Inguinopelvic lymphadenectomy following positive inguinal sentinel lymph node biopsy in melanoma: true frequency of synchronous pelvic metastases. Ann Surg Oncol. 2011;18:3309–15.PubMedCrossRefGoogle Scholar
  33. 33.
    Klop WM, Veenstra HJ, Vermeeren L, Nieweg OE, Balm AJ, Lohuis PJ. Assessment of lymphatic drainage patterns and implications for the extent of neck dissection in head and neck melanoma patients. J Surg Oncol. 2011;103:756–60.PubMedCrossRefGoogle Scholar
  34. 34.
    Leong SP. Role of selective sentinel lymph node dissection in head and neck melanoma. J Surg Oncol. 2011;104:361–8.PubMedGoogle Scholar
  35. 35.
    Namm JP, Chang AE, Cimmino VM, Rees RS, Johnson TM, Sabel MS. Is a level III dissection necessary for a positive sentinel lymph node in melanoma? J Surg Oncol. 2011;105:225–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Spillane AJ, Haydu L, McMillan W, Stretch JR, Thompson JF. Quality assurance parameters and predictors of outcome for ilioinguinal and inguinal dissection in a contemporary melanoma patient population. Ann Surg Oncol. 2011;18:2521–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Santinami M, Carbone A, Crippa F, et al. Radical dissection after positive groin sentinel biopsy in melanoma patients: rate of further positive nodes. Melanoma Res. 2009;19:112–8.PubMedCrossRefGoogle Scholar
  38. 38.
    van der Ploeg IM, Kroon BB, Valdes Olmos RA, Nieweg OE. Evaluation of lymphatic drainage patterns to the groin and implications for the extent of groin dissection in melanoma patients. Ann Surg Oncol. 2009;16:2994–9.PubMedCrossRefGoogle Scholar
  39. 39.
    van der Ploeg IM, Valdes Olmos RA, Kroon BB, Nieweg OE. Tumor-positive sentinel node biopsy of the groin in clinically node-negative melanoma patients: Superficial or superficial and deep lymph node dissection? Ann Surg Oncol. 2008;15:1485–91.PubMedCrossRefGoogle Scholar
  40. 40.
    Delman KA, Kooby DA, Rizzo M, Ogan K, Master V. Initial experience with videoscopic inguinal lymphadenectomy. Ann Surg Oncol. 2011;18:977–82.PubMedCrossRefGoogle Scholar
  41. 41.
    Ising IM, Bembenek A, Gutzmer R, Kockerling F, Moesta KT. Enhanced postoperative lymphatic staging of malignant melanoma by endoscopically assisted iliacoinguinal dissection. Langenbecks Arch Surg. 2011;397:429–36.PubMedCrossRefGoogle Scholar
  42. 42.
    Spillane AJ, Tucker M, Pasquali S. A pilot study reporting outcomes for melanoma patients of a minimal access ilio-inguinal dissection technique based on two incisions. Ann Surg Oncol. 2011;18:970–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Lamb BW, Sevdalis N, Taylor C, Vincent C, Green JS. Multidisciplinary team working across different tumour types: analysis of a national survey. Ann Oncol. 2011;23:1293–300.PubMedCrossRefGoogle Scholar
  44. 44.
    Lamb BW, Brown KF, Nagpal K, Vincent C, Green JS, Sevdalis N. Quality of care management decisions by multidisciplinary cancer teams: a systematic review. Ann Surg Oncol. 2011;18:2116–25.PubMedCrossRefGoogle Scholar
  45. 45.
    Wright FC, Lookhong N, Urbach D, Davis D, McLeod RS, Gagliardi AR. Multidisciplinary cancer conferences: identifying opportunities to promote implementation. Ann Surg Oncol. 2009;16:2731–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Nat Cancer Inst. 2010;102:493–501.PubMedCrossRefGoogle Scholar
  47. 47.
    Eggermont AM, Robert C. New drugs in melanoma: it’s a whole new world. Eur J Cancer. 2011;47:2150–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Efficacy study of ipilimumab versus placebo to prevent recurrence after complete resection of high-risk stage III melanoma. http://clinicaltrial.gov/ct2/show/NCT00636168?term=melanoma+ipilimumab+stage+III&rank=4. Accessed 16 Jan 2012.
  49. 49.
    Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.PubMedCrossRefGoogle Scholar
  50. 50.
    Arkenau HT, Kefford R, Long GV. Targeting BRAF for patients with melanoma. Br J Cancer. 2011;104:392–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Burmeister BH, Henderson MA, Ainslie J, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol. 2012;13:589–97.PubMedCrossRefGoogle Scholar
  52. 52.
    Spillane AJ, Cheung BL, Stretch JR, et al. Proposed quality standards for regional lymph node dissections in patients with melanoma. Ann Surg. 2009;249:473–80.PubMedCrossRefGoogle Scholar
  53. 53.
    Xing Y, Badgwell BD, Ross MI, et al. Lymph node ratio predicts disease-specific survival in melanoma patients. Cancer. 2009;115:2505–13.PubMedCrossRefGoogle Scholar
  54. 54.
    Balch CM, Durant JR, Bartolucci AA. The impact of surgical quality control in multi-institutional group trials involving adjuvant cancer treatments. Ann Surg. 1983;198:164–7.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2012

Authors and Affiliations

  • Sandro Pasquali
    • 1
    • 2
    • 8
  • Andrew J. Spillane
    • 1
    • 2
    • 3
    • 4
    • 5
  • Johannes H. W. de Wilt
    • 6
  • Kirsten McCaffery
    • 7
  • Carlo R. Rossi
    • 8
    • 9
  • Michael J. Quinn
    • 1
    • 2
    • 3
    • 4
  • Robyn P. Saw
    • 1
    • 2
    • 3
    • 4
  • Kerwin F. Shannon
    • 1
    • 2
    • 3
    • 4
  • Jonathan R. Stretch
    • 1
    • 2
    • 3
    • 4
  • John F. Thompson
    • 1
    • 2
    • 3
    • 4
  1. 1.Melanoma Institute AustraliaNorth SydneyAustralia
  2. 2.Sydney Medical SchoolThe University of SydneySydneyAustralia
  3. 3.The Mater HospitalNorth SydneyAustralia
  4. 4.Royal Prince Alfred HospitalCamperdownAustralia
  5. 5.Royal North Shore HospitalSt. LeonardsAustralia
  6. 6.Department of SurgeryRadboud University, Nijmegen Medical CenterNijmegenThe Netherlands
  7. 7.School of Public HealthThe University of SydneySydneyAustralia
  8. 8.Department of Surgical and Oncological SciencesUniversity of PadovaPaduaItaly
  9. 9.Melanoma and Sarcoma UnitVeneto Institute of OncologyPaduaItaly

Personalised recommendations